Natalie Blanchard
Psychiatric/Mental Health · Broussard, LANPI 1265437438
Payments from drug & device makers
Across 700 payments — averaging $17.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
- Otsuka America Pharmaceutical, Inc.$1K
- Alkermes, Inc.$956
- Axsome Therapeutics, Inc.$690
- Corium, LLC$661
- plus $5K from 32 others
What the payments were for
- Food & beverage$12,240100%
- Education$310%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 161 | $2,016 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 70 | $1,497 |
| Otsuka America Pharmaceutical, Inc. | 57 | $1,005 |
| Alkermes, Inc. | 63 | $956 |
| Axsome Therapeutics, Inc. | 27 | $690 |
| Corium, LLC | 39 | $661 |
| Lundbeck LLC | 30 | $655 |
| Johnson & Johnson | 24 | $623 |
| Noven Therapeutics, LLC | 32 | $562 |
| Neurocrine Biosciences, Inc. | 22 | $419 |
| Tris Pharma Inc | 22 | $407 |
| Vanda Pharmaceuticals Inc. | 20 | $380 |
| Braeburn Inc. | 16 | $347 |
| Takeda Pharmaceuticals U.S.A., Inc. | 14 | $257 |
| Bausch Health US, LLC | 12 | $231 |
| Teva Pharmaceuticals USA, Inc. | 12 | $213 |
| Sunovion Pharmaceuticals Inc. | 15 | $205 |
| Indivior Inc. | 9 | $197 |
| Lilly USA, LLC | 8 | $147 |
| Merck | 6 | $88 |
| Ironshore Pharmaceuticals Inc. | 4 | $87 |
| AstraZeneca | 5 | $75 |
| E.r. Squibb & Sons, L.L.C. | 3 | $68 |
| Amgen | 4 | $56 |
| Neos Therapeutics, LP | 3 | $55 |
| Supernus Pharmaceuticals, Inc. | 3 | $49 |
| Kowa Pharmaceuticals America, Inc. | 3 | $43 |
| Astellas Pharma US Inc | 3 | $41 |
| Novo Nordisk | 2 | $41 |
| Sage Therapeutics, LLC | 1 | $35 |
| GSK | 2 | $32 |
| Currax Pharmaceuticals LLC | 2 | $30 |
| Eisai Inc. | 1 | $22 |
| Bayer | 1 | $20 |
| Noven Pharmaceuticals, Inc. | 1 | $17 |
| Almatica Pharma LLC | 1 | $16 |
| Exact Sciences | 1 | $16 |
| Idorsia Pharmaceuticals US Inc | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CAPLYTA$234
- INVEGA SUSTENNA$150
How this compares
$12,271 in reported general payments places this provider in the 95th percentile of 615 psychiatric/mental health providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 11 | $39,770 |
| Trazodone Hcl | 20 | $434 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 14 | $388 |
| Duloxetine Hcl | 34 | $351 |
| Oxcarbazepine | 12 | $202 |
| Escitalopram Oxalate | 11 | $82 |
| Quetiapine Fumarate | 16 | $76 |
| Clonazepam | 24 | $64 |
| Lamotrigine | 20 | $63 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna | $623 | $39,77011 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 615 psychiatric/mental health providers in Louisiana.
Other psychiatric/mental health in Broussard
- Amber LittlefieldBroussard$225K
- Aimee Chantelle BroussardBroussard$13K
- Amy LacoutureBaton Rouge$663K
- Amanda EymardHouma$617K
- Timothy PellegrinHouma$210K
- Melissa GuilbeauLafayette$122K
- Kimberly ForcinelShreveport$92K
- Sattaria DilksLake Charles$57K
- Joe TaylorHammond$38K
- Lecy AlbaradoScott$34K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.